Moxifloxacin-matching Placebo

DRUG5 trials

Sponsors

Actelion, Janssen Research & Development, LLC, Alexion Pharmaceuticals, Inc.

Conditions

CardiodynamicsHealthyPharmacokineticsSafetyTolerability

Phase 1

Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

CompletedNCT02206204

ActelionCardiodynamics, Pharmacokinetics, Safety +1

Start: 2012-06-30End: 2012-11-30Updated: 2014-08-01

A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants

CompletedNCT02271438

Janssen Research & Development, LLCHealthy

Start: 2014-10-31End: 2015-05-31Updated: 2016-06-06

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

CompletedNCT03606057

Janssen Research & Development, LLCHealthy

Start: 2018-07-13End: 2019-02-28Updated: 2020-03-03

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

CompletedNCT04660890

Alexion Pharmaceuticals, Inc.Healthy

Start: 2020-12-12End: 2021-03-16Updated: 2021-12-29

A Study of the Cardiac Effects of Danicopan in Healthy Adults

CompletedNCT05016206

Alexion Pharmaceuticals, Inc.Healthy

Start: 2018-07-26End: 2018-10-12Updated: 2021-08-23

Related Papers

Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.

2017-10-2821 citations